The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $10.68

Today's change0.00 0.00%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.
 

Ironwood Pharmaceuticals Inc

Nasdaq: IRWD
Last

(U.S.) $10.68

Today's change0.00 0.00%
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

Ironwood Pharmaceuticals Inc closed at (U.S.)$10.68.

Over the last five days, shares have lost 3.35% and are down 30.29% for the last year to date. This security has underperformed the S&P 500 by 15.30% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $10.68
  • High--
  • Low--
  • Bid / Ask(U.S.) $0.01 / (U.S.) $200.00K
  • YTD % change-30.29%
  • Volume0
  • Average volume (10-day)1,589,554
  • Average volume (1-month)1,659,236
  • Average volume (3-month)1,837,705
  • 52-week range(U.S.) $10.15 to (U.S.) $17.11
  • Beta1.41
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.14
Updated September 3 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-144.07%

Although this company's net profit margin is negative, it is above the industry average and implies that Ironwood Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue28293817
Total other revenue--------
Total revenue28293817
Gross profit20292517
Total cost of revenue80130
Total operating expense70577154
Selling / general / administrative33303129
Research & development29272725
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-42-28-33-37
Interest income (expense), net non-operating-6-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-48-33-38-42
Income after tax-48-33-38-42
Income tax, total----00
Net income-48-33-38-42
Total adjustments to net income--------
Net income before extra. items-48-33-38-42
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-48-33-38-42
Inc. avail. to common incl. extra. items-48-33-38-42
Diluted net income-48-33-38-42
Dilution adjustment--0--0
Diluted weighted average shares142141140139
Diluted EPS excluding extraordinary itemsvalue per share-0.34-0.24-0.27-0.30
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.34-0.24-0.27-0.30